IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant” October 22, 2025 Read More »
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida’s Department of Psychiatry and Behavioral Neurosciences October 14, 2025 Read More »
IGC Pharma’s Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer’s Disease October 7, 2025 Read More »
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer’s Trial September 29, 2025 Read More »
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology September 24, 2025 Read More »
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial September 22, 2025 Read More »
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer’s Detection September 9, 2025 Read More »
IGC Pharma Expands CALMA Phase 2 Trial to Island Health’s Royal Jubilee Hospital in Canada September 2, 2025 Read More »
